What is Halozyme Therapeutics 5-Year EBITDA Growth Rate?
Halozyme Therapeutics's EBITDA per Share for the
three
months ended in Dec. 2023 was $0.97.
During the past 12 months, Halozyme Therapeutics's average EBITDA Per Share Growth Rate was 50.10% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 46.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Halozyme Therapeutics was 46.10% per year. The lowest was -97.20% per year. And the median was -7.80% per year.
Competitive Comparison of Halozyme Therapeutics's 5-Year EBITDA Growth Rate
For the Biotechnology subindustry, Halozyme Therapeutics's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Halozyme Therapeutics's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Halozyme Therapeutics's 5-Year EBITDA Growth Rate falls into.
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
Halozyme Therapeutics 5-Year EBITDA Growth Rate Related Terms
Thank you for viewing the detailed overview of Halozyme Therapeutics's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Halozyme Therapeutics (Halozyme Therapeutics) Business Description
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HALO has been successfully added to your